Q: Please,your analysis/comments on this company.Thanks.
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: Can you please provide an update? It is suffering. Do you still like it?
Thank you,
Karim.
Thank you,
Karim.
Q: Kalvista flunked a drug trial and the stock was down 20% premarket. Now the stock is up 4%. Any idea why?
Q: I have nothing relating to the Healthcare sector and would like to fill this gap. Considering both the Canadian and US markets, what are your best suggestions?
Much appreciated. RAM
Much appreciated. RAM
Q: Further to a previous question about your suggestion for 4-5 core holdings in the U.S., I notice that you did not suggest any Healthcare stocks. Could you comment on this - do you like any? I don't see much in Canada to choose from.
Thanks so much
Margaret
Thanks so much
Margaret
Q: Would you have or have access to y/e expected rev & cash flow numbers . Is there anything expected that would bring the stock value up.
Thanks
Thanks
Q: What do you guys think of this name after the Lupus drug treatment announcement the other day? I recognize it's speculative.
Jason
Jason
Q: Dear 5i,
I would appreciate you comments on the following questions:
1. Does key management have meaningful share ownership in the company?
2. How long has key management been at the helm?
3. Would you expect any further dividend cuts?
4. Do you think their debt is manageable and reasonable?
5. Do they own any real estate. If yes, how much worth?
thanks
I would appreciate you comments on the following questions:
1. Does key management have meaningful share ownership in the company?
2. How long has key management been at the helm?
3. Would you expect any further dividend cuts?
4. Do you think their debt is manageable and reasonable?
5. Do they own any real estate. If yes, how much worth?
thanks
Q: NXPI along with KODIAK Science which is up more than 100% in the last month, what are your opinions of the two stocks?
About the PE ratio - on my Globe Invest it has for instance 98.4 TTM (I do not know what that is), is that number too high for you if you were looking to purchase a stock with that number? What would be a more comfortable number? Thanks for providing info that the average investor would not know. Dennis
About the PE ratio - on my Globe Invest it has for instance 98.4 TTM (I do not know what that is), is that number too high for you if you were looking to purchase a stock with that number? What would be a more comfortable number? Thanks for providing info that the average investor would not know. Dennis
Q: Hi,
What do you think of Vertex? How is it valued relative to peers and what do you think of its growth outlook? Would you buy at these levels?
What do you think of Vertex? How is it valued relative to peers and what do you think of its growth outlook? Would you buy at these levels?
Q: Do you currently have an opinion on AZN?
Q: Listed on Nasdaq as AUPH. After market close today,it was halted pending news.Later it announced positive phase 3 trail results showing that its Voclosporin is much better than Standard of Care in Lupus Nephritis.It plans to file NDA submission to FDA in 1st half of 2020,There will be a conference call @ 8.30am ET on Dec 5 .AUPH closed @ US$8.39 up 0.41 on 4.9m shares.However in After Hours trading it was @ US $18.39 to US$19.00 on total 10.6m shares.Thinking of selling my 1.5% position,p/p Can$8.33 especially if the Price is around US$18.39 to 19.00.Should I sell all or partial.Please provide your usual great advices & services.Thanks
Q: I have been very fortunate to have my second 10-bagger with ARWR bought at $4 in 2017 (after some earlier losses). It has been running very well recently but is down to-day on the news that they are issuing 4m shares at $58, well below yesterdays close of $68.66. Why would they issue new shares so far below the recent market? Is there something here to worry about?
Thanks for your great service, Bob.
Thanks for your great service, Bob.
Q: Gud has now 51% and yet BIO trades at $10.15 BRL, about 16% below the offer price.
What do you read into this. Is there an opportunity here ? Can I buy BIO, should I ?
Will GUD offer less than they offered the private previous owners ? When will GUD start reporting earnings from this acquisition ? Do they need all the shares to do so ?
Finally do you see more analysts stepping in now with this new acquisition, maybe one or two will make it their top pick in 2020 ? Thoughts?Thanks
What do you read into this. Is there an opportunity here ? Can I buy BIO, should I ?
Will GUD offer less than they offered the private previous owners ? When will GUD start reporting earnings from this acquisition ? Do they need all the shares to do so ?
Finally do you see more analysts stepping in now with this new acquisition, maybe one or two will make it their top pick in 2020 ? Thoughts?Thanks
Q: Hi there,
This is a cancer biotech focused on melanoma and cervical cancer. It sounds like several promising trials are underway. I just read about it on Seeking Alpha and CNBC shows 8 analysts covering with 5 strong buy and 3 buy recommendations with a consensus target of $35 vs a current price of $22.83. What are your thoughts regarding a position within a TFSA?
ThanksQ
This is a cancer biotech focused on melanoma and cervical cancer. It sounds like several promising trials are underway. I just read about it on Seeking Alpha and CNBC shows 8 analysts covering with 5 strong buy and 3 buy recommendations with a consensus target of $35 vs a current price of $22.83. What are your thoughts regarding a position within a TFSA?
ThanksQ
Q: what your comments on this one now ?
Q: Your view on Aileron Therapeutics please
Q: Can I please get your opinion of AbbVie.
Thanks
Dave
Thanks
Dave
Q: Hi Peter and Ryan,
I noticed CLVS had a good run lately. I am wondering whether the fundamental has been changed. Is it a good buy now?
Please also provide a few (CAD and US) names that are stable for long investment in the next few months, particularly with good valuation. It is almost RRSP season.
Thanks,
Yiwen
I noticed CLVS had a good run lately. I am wondering whether the fundamental has been changed. Is it a good buy now?
Please also provide a few (CAD and US) names that are stable for long investment in the next few months, particularly with good valuation. It is almost RRSP season.
Thanks,
Yiwen
Q: Stock down on heavy volume but I can't see any trigger. What do you think?